PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Ne
The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).
| Condition(s) | Persistent Pulmonary Hypertension of the Newborn |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs). |
| Who can participate | Inclusion Criteria: * Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age. Exclusion Criteria: * Patients will be excluded if they are diagnosed with lethal congenital anomalies * structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale * structural gastrointestinal tract abnormality that could interfere with meconium passage * congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia |
| Ages | 12 Months |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Medical College of Wisconsin |
| Locations | Milwaukee, Wisconsin, United States |
| Start date | 2006-01 |
| NCT ID | NCT00710177 |
| Official listing | https://clinicaltrials.gov/study/NCT00710177 |